Savara (SVRA) Short-Term Debt issuances (2016 - 2017)
Savara (SVRA) posted quarterly Short-Term Debt issuances of -$3.6 million for Q4 2017, down 134.43% year-over-year from $10.4 million in Q4 2016, and down 124.56% quarter-over-quarter from $14.5 million in Q2 2017.
Powered by 
Analysis
Savara (SVRA) Short-Term Debt issuances (2016 - 2017) Analysis & Trends
Savara (SVRA) has reported Short-Term Debt issuances for 2 consecutive years, with -$3.6 million the latest figure, recorded in Q4 2017.
- In Q4 2017, Short-Term Debt issuances fell 134.43% year-over-year to -$3.6 million; the TTM figure through Dec 2017 stood at $11.3 million (changed N/A YoY), while the FY2018 annual figure was $9.4 million, down 17.32% from the prior year.
- Short-Term Debt issuances fell to -$3.6 million in Q4 2017 per SVRA's latest filing, from $14.5 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $14.5 million in Q2 2017 and bottomed at -$3.6 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | -3.57 Mn |
| Jun 30, 2017 | 14.53 Mn |
| Mar 31, 2017 | 368,000.00 |
| Dec 31, 2016 | 10.36 Mn |